Summary TNP-470, a synthetic analogue of fumagillin first isolated from Aspergillus fumigatus, is known to be a potent anti-angiogenic compound. The combined effects on tumour growth and tumour angiogenesis of TNP-470 and hyperthermia were investigated. The tumour used was SCCVII carcinoma of the C3H/He mouse. The tumour response was evaluated by the tumour growth (TG) time assay. The TG time is the time required for one-half of the treated tumours to reach three times the initial tumour volume. Significant delay of tumour growth was observed by TNP-470 alone (100 mg kg-1 x 2 or x 4), indicating that TNP-470 alone has antitumour effect in vivo. When TNP-470 (100 mg kg-1 x 2 or x 4) was administered after hyperthermia at 44°C, the TG times of the combined treatment were significantly longer than those of heat alone (44°C) or TNP-470 (100 mg kg-I x 2 or x 4) alone. However, the TG time of combined treatment with TNP-470 and hyperthermia at 42°C was quite similar to that of TNP-470 alone. This conflicting result on the combined effect of TNP-470 and hyperthermia may be related to the temperature-dependent vascular damage by hyperthermia. Dose-dependent inhibition of angiogenesis by TNP-470 was demonstrated in microangiograms obtained 4 days and 7 days after hyperthermia (44°C for 30 min). It is, thus, suggested that the combined effect of TNP-470 and hyperthermia is attributable to the inhibition of angiogenesis by TNP-470 following heat-induced vascular damage.
Angiogenesis is critical for the growth of solid tumours and metastasis (Folkman, 1990) . Therefore, anti-angiogenic therapy is probably one of the most promising strategies for restricting tumour growth (Denekamp, 1991; Bricknell and Harris, 1991; Brem and Folkman, 1993) . TNP-470, a synthetic analogue of fumagillin first isolated from Aspergillus fumigatus, is known to be a potent anti-angiogenic compound (Ingber et al., 1990; Kusaka et al., 1991) . It has been found to suppress not only endothelial cell growth in vitro, but also tumour growth in vivo (Brem and Folkman, 1993; Ingber et al., 1990; Kusaka et al., 1991 Kusaka et al., , 1994 Toi et al., 1994; Yanase et al., 1993; Yamaoka et al., 1993a,b) . The antitumour effect in vivo was thought to be due to inhibition of angiogenesis.
Blood perfusion plays an important role in the tissue damage by hyperthermia. Tissue temperature is dependent on blood flow rate, and it also controls the intratumoral microenvironment, which affects the thermosensitivity of the tissue (Song, 1984; Reinhold and Endrich, 1986; Vaupel, 1988) . In addition, hyperthermia itself selectively destroys the tumour vasculature at a high heat dose (Song, 1984; Reinhold and Endrich, 1986; Vaupel, 1988; Nishimura et al., 1988a,b) . In previous studies, we demonstrated that heating at 44°C for 30 min almost destroys murine tumour vasculature and angiogenesis occurs from the peripheral zone of the tumour 3 days after heating (Nishimura et al., 1988a) . Therefore, it is an interesting question whether inhibition of the angiogenesis by an angiogenesis inhibitor may enhance the effect of hyperthermia.
In the present study, we examined the effects of TNP-470 on hyperthermia-induced growth delay of SCCVII tumours. The effect of TNP-470 on tumour angiogenesis after hyperthermia was investigated quantitatively by using microangiography.
Materials and methods Animal tumour Eight-week old C3H/He male mice were used throughout the study. The mice were obtained from Shizuoka Laboratory Animal Center (Shizuoka, Japan), and kept in our microorganism-free animal facility. They were provided with sterilised mouse pellets and water ad libitum.
SCCVII carcinoma of the C3H/He mice was used. The SCCVII tumour is a squamous carcinoma that arises spontaneously in the abdominal wall of a C3H mouse (Hirst et al., 1982) . The SCCVII tumour cell line was thawed from original frozen stocks and maintained by alternate passage in syngeneic mice and cell culture in Eagle's minimum essential medium supplemented with 12.5% fetal bovine serum. Some of the biological characteristics of the SCCVII tumour were described elsewhere (Hirst et al., 1982) . Approximately 1 x 105 SCCVII tumour cells collected from monolayer cultures were inoculated s.c. into the right thigh of the C3H/He male mice both for tumour growth (TG) time assay and for microangiography. Experiments were performed when the tumours reached 8-10 mm in diameter. Drug TNP-470 was kindly provided by Takeda Chemical Industries, Osaka, Japan. TNP-470 was dissolved in 5% arabic gum-saline solution. For the TG time assay, two or four doses of TNP-470 (100 mg kg-') were administered s.c. into the back of the mice.When TNP-470 was administered in combination with hyperthermia, the first dose was given 3 h after heat treatment (day 0). Second, third and fourth doses were administered on days 3, 7 and 10 respectively. For analysis of tumour angiogenesis by microangiography, two doses of TNP-470 (50 mg kg-' or 100 mg kg-1) were administered s.c. 3 h after hyperthermia (44°C for 30 min) and on day 3.
Hyperthermia
Hyperthermia was achieved by immersing the animal's foot in a water bath. Intratumoral thermometry data have been described elsewhere (Nishimura et al., 1988a (Nishimura and Urano, 1993) . Each treatment group consisted of 10-12 mice. Statistical analysis between the treatment groups was performed using Student's t-test, and P < 0.05 was regarded as significant difference.
Analysis of tumour angiogenesis Vascular damage and angiogenesis after hyperthermia were evaluated by microangiography and correlative histological sections. The technique of microangiography was described previously (Nishimura et al., 1988a) . Briefly, a filtered barium sulphate solution (0.25 g ml-') was injected at a pressure of 150 mmHg after flushing the circulatory system with warmed heparinised saline. When the muscular vasculature of the hind limb was not opacified sufficiently, the mouse was excluded from the study to avoid a poor filling artifact. In the present study, 2 of 42 mice used for microangiography were excluded from the analysis because of the poor filling artifact. After the tumour was fixed with 10% buffered formalin, contact radiographs of 1-mm-thick tumour slices were obtained. The tumour slice was cut along a sagittal direction through its centre with as much surrounding normal tissue as posssible. Correlative histological sections 4 Mm thick were prepared for each tumour slice and stained with haematoxylin and eosin.
Microangiographic changes were analysed quantitatively as follows (Nishimura et al., 1988a,b) . Opacified vascularised areas and avascular areas in a tumour were demarcated on an enlarged microangiogram (approximately x 10), and the vascularised areas (V) and the entire tumour area (T) were measured using a digital planimeter. Thereafter, the percentage of vascularised area was calculated as V/T x 100 in each microangiogram. The mean and s.e. of the percentage of vascularised area was obtained for each group. Each group consisted of 4-9 angiograms (mean 6).
Results

TG time assay
The results of TG time assay for TNP-470 are shown in Table I . The TG times of control tumours and those treated with TNP-470 (100 mg kg-1x 2) were 7.3 days (95% CL:
6.6-8.0 days) and 8.7 days (8.3-9.2 days) respectively. The difference between these two TG times was statistically significant (P<0.05), indicating that TNP-470 alone has an anti-tumour effect in vivo. When four doses of TNP-470 were administered, the TG time was further increased.
Figures 1 and 2 show the tumour growth curves for tumours treated with hyperthermia at 42°C and 44°C with or without TNP-470 (100 mg kg-' x 2). Hyperthermia alone at 42°C did not result in any growth delay compared with control tumours, while hyperthermia at 44°C resulted in significant growth delay compared with untreated control tumours (P <0.05). When TNP-470 was administered following hyperthermia at 42°C, the tumour growth curve Hyperthermia and angiogenesis inhibitor Y Nishimura et al ! 271 was not different from the growth curve for tumours treated with TNP-470 alone (Figure 1) . However, when TNP-470 was administered after hyperthermia at 44°C, significant tumour growth delay was observed compared with those for each treatment alone (Figure 2 Figure 3 shows the tumour growth curves for tumours treated with hyperthermia at 44°C with or without (100 mg kg-x 4). Although administration of four doses of TNP-470 caused apparent suppression of the tumour growth compared with untreated control tumours, tumour growth was not inhibited completely. On the other hand, when TNP-470 was administered following hyperthermia at 44°C, complete inhibition of tumour growth was observed for 6 days after hyperthermia. The median TG time of the combination was 16.4 days (14.9 -18.1 days), which was significantly longer than those of TNP-470 alone (100 mg kg-1 x 4) or hyperthermia alone at 44°C (P <0.001).
Tumour angiogenesis Figure 4 shows the changes in percentage of vascularised area after heating at 44°C for 30 min. In the previous study, percentage of vascularised area of untreated SCCVII carcinoma was 100+ 0%, and no focal avascular area or necrotic area was observed histologically for untreated SCCVII tumours (Nishimura et al., 1988a Figure Sa) . The percentage of vascularised area increased rapidly at day 4 and day 7 for tumours treated with hyperthermia alone. In the microangiograms, tapering capillary sprouts indicating angiogenesis were observed at the inner edge of the opacified vascularised area (Figure 5b ).
For tumours treated with TNP-470 (50 mg kg-1 or 100 mg kg-') following hyperthermia, the percentage of vascularised area increased more slowly than tumours treated with hyperthermia alone (Figures 4 and 5) . Although complete inhibition of angiogenesis was not observed even when 100 mg kg-' TNP-470 was administered twice weekly, the percentage of vascularised area of tumours treated with TNP-470 (100 mg kg-') at day 4 and day 7 were significantly smaller than those of tumours treated with hyperthermia alone at day 4 and day 7 (P=0.005 and P=0.018 respectively). The difference in the percentage of vascularised area at day 4 was borderline significance between TNP-470 (50 mg kg-') and the hyperthermia alone group (P=0.08). (Yamaoka et al., 1993a,b; Teicher et al., 1994 ; Time after treatment (days) Kamei et al., 1993; Toi et al., 1993) . In this study, the or hyperthermia alone (Figures 2 and 3 o-AC.~., , , (Kusaka et al., 1994) .
Although the combined effect of TNP-470 and hyperthermia was noted at 44°C heating, it was not demonstrated at 42°C (Figures 1 and 2 ). Apparently vascular damage by hyperthermia is temperature dependent (Song, 1984; Reinhold and Endrich, 1986; Vaupel, 1988; Nishimura et al., 1988a) . In the previous study, we demonstrated that 95% of tumour vasculature of the SCCVII tumour was destroyed 24 h after heating at 44°C, whereas only 24% of tumour vasculature was destroyed 24 h after heating at 42°C (Nishimura et al., 1988a) . Because heat effects are also time dependent, severe vascular damage may occur when hyperthermia is applied for longer periods at 42°C. It is apparent that heat dose is more important than the heating temperature itself. TNP-470 might have greater effects after a high heat dose than a low heat dose, because significant portions of tumour vasculature should be damaged by hyperthermia before administrating an angiogenesis inhibitor.
In clinical hyperthermia only limited portions of the tumour volume can be heated to 43-44°C even for superficial tumours. In addition, the tumour vasculature of human tumours is considered to be more resistant to heat than the murine tumour vasculature (Waterman et al., 1987) . Thus, it remains unclear whether this particular combination between TNP-470 and high temperature hyperthermia will have clinical relevance. However, CT scans obtained after clinical thermoradiotherapy showed a clear low-density area in well-heated human tumours, which was confirmed histologically to be coagulation necrosis (Hiraoka et al., 1987; Nishimura et al., 1989) . Leopold et al. (1992) reported that 60% of human soft tissue sarcomas treated with preoperative thermoradiotherapy showed tumour necrosis of >80% area in resected specimens. Jo et al. (1989) demonstrated that small tumour blood vessels and capillaries in human tumour parenchyma were markedly damaged after thermoradiotherapy. Thus, it is likely that human tumour vasculatures may be severely damaged by several sessions of satisfactory heating combined with radiation therapy. Therefore, TNP-470 may be clinically useful if it is combined with thermoradiotherapy of good heating quality.
In the analysis of tumour angiogenesis by microangiography, significant inhibition of angiogenesis was observed by TNP-470. Although inhibition of angiogenesis by TNP-470 has been demonstrated by a vascular grading system in human nerve sheath tumours (Takamiya et al., 1993) , this study first showed that TNP-470 inhibited tumour angiogenesis in vivo quantitatively. This analysis system of tumour angiogenesis after hyperthermia seems a good model to study angiogenesis of murine tumour vasculature in vivo because hyperthermia at a high heat dose inevitably destroys murine tumour vasculature followed by angiogenesis. In the present study, TNP-470 was given after hyperthermia to investigate its effects on tumour angiogenesis. However, TNP-470 may enhance heat effects when it is administered before heating. Inhibition of tumour angiogenesis by TNP-470 may make the intratumoral environment more acidic and hypoxic, which increases the hyperthermic damage to tissues (Song, 1984; Reinhold and Endrich, 1986; Vaupel, 1988) . Further study to confirm this hypothesis is in progress.
In conclusion, our results indicated that the greater tumour growth delay produced by the combination of TNP-470 and hyperthermia at 44°C resulted from the inhibition of tumour angiogenesis following heat-induced vascular damage. As hyperthermia is a clinically applicable vascular-damaging agent, the combination of hyperthermia and anti-angiogenic treatment seems a promising strategy.
